Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

This study has been terminated.
(Lack of accrual)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Edward Neuwelt, OHSU Knight Cancer Institute Identifier:
First received: December 10, 2003
Last updated: April 19, 2017
Last verified: April 2017

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug/Agent Toxicity by Tissue/Organ
Drug: Rituxan
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Etoposide phosphate
Drug: Carboplatin
Drug: Sodium thiosulfate
Drug: Neupogen
Drug: Neulasta
Drug: Cytarabine
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen

Resource links provided by NLM:

Further study details as provided by OHSU Knight Cancer Institute:

Primary Outcome Measures:
  • Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years. [ Time Frame: 2 years ]
    Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions.

Secondary Outcome Measures:
  • Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response [ Time Frame: 5 years ]
    Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.

  • Progression-free Survival Assessed by Clinical and Radiographic Response From First Day of Treatment Until Tumor Progression [ Time Frame: 5 years ]
  • Quality of Life Assessed by EORTC QOL Before Treatment and Then Every 3 Months [ Time Frame: 5 years ]
  • Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment [ Time Frame: 2 years ]
  • Effect of Sodium Thiosulfate (STS) on Granulocytes and Erythrocytes Assessed by Complete Blood Count Lab Values Done Weekly During Treatment [ Time Frame: 2 years ]

Enrollment: 17
Study Start Date: January 2003
Study Completion Date: December 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All subjects Drug: Rituxan
Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
Other Name: Rituximab
Drug: Cyclophosphamide
Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
Drug: Etoposide
Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
Drug: Etoposide phosphate
Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
Drug: Carboplatin
Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
Drug: Sodium thiosulfate

Dose: 4 hrs post carboplatin = 20gm/m2;

Dose: 8 hrs post carboplatin = 16gm/m2

Infused IV x 2 days

Other Name: STS
Drug: Neupogen
48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
Other Names:
  • G-CSF
  • filgrastim
Drug: Neulasta
Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
Other Name: Pegfilgrastim
Drug: Cytarabine
Dose: 40mg on Day 14 following chemotherapy

Detailed Description:



  • Determine the efficacy of rituximab, carboplatin, cyclophosphamide, etoposide or etoposide phosphate and cytarabine administered in conjunction with osmotic blood-brain barrier disruption and high-dose sodium thiosulfate, in terms of complete response rate, in patients with refractory or recurrent primary CNS lymphoma.


  • Determine the overall survival and 2-year progression-free survival of patients treated with this regimen.
  • Determine the quality of life and cognitive function of patients treated with this regimen.
  • Determine the neurotoxicity of this regimen in these patients.
  • Determine the percentage of patients with ototoxicity over time after treatment with this regimen.
  • Determine the effect of delayed administration of sodium thiosulfate on granulocyte and erythrocyte counts in these patients.

OUTLINE: This is a multicenter study.

Patients receive rituximab IV on day 1. On days 2 and 3, patients receive carboplatin intra-arterially over 10 minutes, cyclophosphamide IV over 10 minutes, and etoposide or etoposide phosphate IV over 10 minutes in conjunction with blood-brain barrier disruption. Patients also receive high-dose sodium thiosulfate IV over 15 minutes administered 4 and 8 hours after carboplatin on days 2 and 3 and intraventricular or intrathecal cytarabine on day 14. Beginning 48 hours after the last dose of chemotherapy, patients receive filgrastim (G-CSF)* subcutaneously (SC) daily for 7-10 days or until blood counts recover. Treatment repeats every 4 weeks for up to 12 courses.

NOTE: * Alternatively, patients may receive a single dose of pegfilgrastim SC, administered 48 hours after the completion of chemotherapy

Patients with intraocular lymphoma also receive methotrexate intravitreally twice weekly until the vitreous is clear of cells by slit lamp exam; once weekly for 1 month; and then monthly for 1 year.

Quality of life is assessed at baseline, every 3 months during treatment, within 30 days of final treatment, then every 6 months for 1 year, and then annually thereafter.

Patients are followed monthly for 3 months, every 2 months for 8 months, every 3 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 11-25 patients will be accrued for this study within 7-10 years.


Ages Eligible for Study:   18 Months to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Signed informed consent form in accordance with institutional guidelines
  • Histologically or cytologically confirmed primary CNS lymphoma documented by brain biopsy or cerebrospinal fluid or vitrectomy analysis
  • CD20 positive disease
  • Progressive or relapsed disease during or after completion of prior methotrexate-based chemotherapy
  • Aged 18 months to 75 years
  • Performance status ECOG 0-3 OR Karnofsky 30-100%
  • Hematocrit at least 25% (transfusion or epoetin alfa allowed)
  • Absolute granulocyte count at least 1,200/mm^3
  • Platelet count at least 100,000/mm^3 OR at least lower limit of normal
  • Bilirubin no greater than 2.0 times upper limit of normal
  • Creatinine less than 1.8 mg/dL
  • Calculated Creatinine clearance (CrCl) at least 50 mL/min
  • Adequate cardiac function to tolerate general anesthesia
  • Adequate pulmonary function to tolerate general anesthesia
  • Available for follow-up for 1 year post therapy
  • Fertile patients must use effective contraception for a minimum of 2 months before and during study participation


  • Radiographic signs of intra-cranial herniation and/or spinal block
  • HIV positive
  • Systemic lymphoma
  • Positive serum HCG, pregnant or lactating
  • Allergy to study agents
  • Hepatitis B or hepatitis C positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00074165

United States, Ohio
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute
Cincinnati, Ohio, United States, 45220
United States, Oregon
Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States, 97239-3098
Sponsors and Collaborators
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Edward A. Neuwelt, MD OHSU Knight Cancer Institute
  More Information

Responsible Party: Edward Neuwelt, Professor, OHSU Knight Cancer Institute Identifier: NCT00074165     History of Changes
Obsolete Identifiers: NCT00261651
Other Study ID Numbers: IRB00000641
5R01CA137488-15 ( US NIH Grant/Contract Award Number )
ONC-02059-LX ( Other Identifier: OHSU Knight Cancer Institute )
641 ( Other Identifier: OHSU eIRB )
7465 ( Other Identifier: OHSU IRB (discontinued number) )
OHSU-641 ( Other Identifier: OHSU IRB )
Study First Received: December 10, 2003
Results First Received: October 10, 2011
Last Updated: April 19, 2017

Keywords provided by OHSU Knight Cancer Institute:
drug/agent toxicity by tissue/organ
intraocular lymphoma
primary central nervous system non-Hodgkin lymphoma
primary central nervous system Hodgkin lymphoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Blood Platelet Disorders
Hematologic Diseases
Neoplasms by Site
Nervous System Diseases
Etoposide phosphate
Sodium thiosulfate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists processed this record on April 28, 2017